DESIGN THERAPEUTICS INC (DSGN)
US25056L1035 - Common Stock
ChartMill assigns a Buy % Consensus number of 48% to DSGN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 6.8. This target is 54.2% above the current price.
DSGN was analyzed by 8 analysts. The buy percentage consensus is at 48. So analysts seem to be rather neutral about DSGN.
In the previous month the buy percentage consensus was at a similar level.
DSGN was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-05-07 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2024-03-20 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-03-20 | Wedbush | Reiterate | Neutral -> Neutral |
| 2023-11-14 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2023-08-15 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2023-08-15 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2023-08-15 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-05-10 | RBC Capital | Maintains | Outperform |
| 2023-05-10 | Wedbush | Maintains | Outperform |
| 2023-05-04 | Goldman Sachs | Upgrade | Sell -> Neutral |
| 2023-03-15 | RBC Capital | Reiterate | Outperform |
| 2022-12-09 | SVB Leerink | Maintains | Outperform |
| 2022-12-08 | RBC Capital | Maintains | Outperform |
| 2022-08-09 | Wedbush | Maintains | Outperform |
| 2022-06-10 | Wedbush | Initiate | Outperform |
| 2022-05-24 | Goldman Sachs | Maintains | Sell |
| 2022-05-10 | SVB Leerink | Maintains | Outperform |
| 2022-05-02 | RBC Capital | Initiate | Outperform |
| 2022-01-19 | Goldman Sachs | Initiate | Sell |
| 2021-04-20 | SVB Leerink | Initiate | Outperform |
| 2021-04-20 | Goldman Sachs | Initiate | Neutral |
| 2021-04-20 | Piper Sandler | Initiate | Overweight |